Company intelligence / Profile preview
FIT Biotech Oy
Tampere, Finlandfit.edu ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
FIT Biotech developed the GTU® vector technology and advanced a lead HIV DNA vaccine candidate into Phase II clinical trials. Other programs targeting cancer and infectious diseases remained in preclinical stages before operations ceased due to bankruptcy in early 2019.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Gene therapyDNA vaccinesAntibody gene delivery technologies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Avacta Group plc—collaboration on gene therapies development.EUREKA Project—Nordic collaboration on HIV vaccine research.
Beyond the preview
Go deeper on FIT Biotech Oy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIT Biotech Oy.